Use of GLP-1 receptor agonists for obesity was associated with a reduced risk of primary open-angle glaucoma (POAG) and ...

The use of GLP-1 receptor agonists corresponded with a lower risk for depression among older adults with type 2 diabetes ...

A boost for the category, and perhaps even a change in the way products are marketed, is anticipated based on research ...

Weight-loss drugs are changing the way people grocery shop and eat. But those spending habits don't necessarily last.

Kidney transplant recipients with type 2 diabetes treated with a new class of anti-obesity drugs were less likely to experience organ failure and survived longer, a new study shows.

GLP-1 receptor agonists were initially approved for glycaemic control in type 2 diabetes and, subsequently, for bodyweight loss in obesity. Following large-scale trials demonstrating that some GLP-1 ...

Expanding coverage and access to GLPs can be beneficial for all with the cooperation of multiple parties in health care.

Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within 1 year.

By now we have all heard about Semaglutide (Ozempic) and Tirzepatide (Mounjaro).  Whether you have used it yourself or know of someone who has, we know how effective ...

GLP-1 receptor agonists show promise in treating alcohol addiction by modulating reward pathways and reducing cravings, offering a novel therapeutic approach.

GLP-1 receptor agonists were associated with better graft and patient survival. Clinical trials are needed to confirm these findings.

Novo Nordisk, the manufacturer of Weggovy, is growing its offerings by creating NovoCare Pharmacy, a direct-to-patient (DTP) ...